Top Story Today
Oral Wegovy Clears Europe's Top Drug Regulator. The Needle-Free GLP-1 Era Just Got Real.
Europe's medicines regulator recommended approval for an oral version of Wegovy, the blockbuster obesity injection, alongside AstraZeneca's breast cancer drug Etcamah. The oral Wegovy pill (25 mg, taken daily) delivered roughly 16.6% body weight loss in clinical trials, nearly matching the injection's results. For the millions of patients who've avoided GLP-1 therapy because of needles, this changes the calculus entirely. Novo Nordisk plans a U.S. launch in early January 2026, though Eli Lilly's rival oral GLP-1 (orforglipron) is already nipping at its heels with superior weight-loss data and no fasting requirement.
Why it matters: A pill that matches the weight-loss power of injectable Wegovy could massively expand the addressable GLP-1 market in Europe, pulling in patients who never would have considered a weekly shot, especially as reimbursement conversations shift from "is obesity a real disease?" to "which formulation do you prefer?"
Read more →Clinical Wins and FDA Decisions
A Cancer Vaccine Just Did What Checkpoint Inhibitors Couldn't in Ovarian Cancer
Small French biotech OSE Immunotherapeutics reported that its cancer vaccine Tedopi, combined with Keytruda, reduced the risk of progression or death by 28% compared to Tedopi alone in a Phase 2 ovarian cancer trial. That's a disease where checkpoint inhibitors have flopped repeatedly because the tumors are "immunologically cold." Full data hit ASCO on May 30, and analysts see 100-200% upside in the stock if the story holds.
Read more →The FDA Decides Thursday if Kids Can Inhale Their Insulin Instead of Injecting It
MannKind's Afrezza faces a May 29 FDA decision that could make it the first needle-free mealtime insulin approved for children as young as four. The Phase 3 trial technically missed its primary endpoint in the full analysis by a hair, but met it after removing one protocol violator. Lung safety in growing kids is the big question regulators will weigh.
Read more →New Approvals
The First New Blood Pressure Mechanism in Over a Decade Just Hit the Market
The FDA approved AstraZeneca's Baxfendy (baxdrostat), a first-in-class drug that shuts off aldosterone production rather than just blocking it. In trials, patients already on multiple meds saw an extra 9.8 mmHg systolic drop versus placebo. AstraZeneca envisions $5 billion in peak sales, though analysts note the path from resistant hypertension niche to blockbuster is far from guaranteed.
Read more →First BCL-2 Inhibitor Approved Specifically for Mantle Cell Lymphoma
BeOne Medicines' Beqalzi (sonrotoclax) earned accelerated FDA approval for relapsed mantle cell lymphoma, posting a 52% response rate in patients who'd failed multiple prior treatments. Designed as a next-gen upgrade to AbbVie's venetoclax, it binds BCL-2 with 20-fold higher affinity and works against the resistance mutation that makes venetoclax stop working.
Read more →Deals, Talent, and Industry Shifts
$290 Million Says Current Migraine Drugs Still Aren't Good Enough
Paragon Therapeutics spinout Mentari Therapeutics raised $290 million and is going public via reverse merger to develop drugs targeting PACAP, a migraine-triggering protein that existing CGRP drugs don't touch. The investor roster (a16z, Blackstone, Perceptive, RTW) is remarkable for a company with zero clinical data, reflecting broad conviction that 40-60% of migraine patients remain undertreated.
Read more →Novartis Built a Faster CAR-T Factory. The Industry Wants to Skip the Factory Entirely.
Novartis's T-Charge platform compresses CAR-T manufacturing from weeks to under two days, with strong early clinical results. But five major pharma companies collectively spent billions acquiring in vivo CAR-T technology that would reprogram immune cells inside the patient's body, no factory needed. The first in vivo approval likely won't come before 2030, giving T-Charge a runway, but the direction of travel is clear.
Read more →The FDA Lost Thousands of Employees This Year. Biotech Is Hiring Every One It Can.
Former FDA Commissioner Stephen Hahn joined Turn Therapeutics, the latest in a wave of regulatory talent leaving the agency for industry. Roughly 600 drug reviewers have reportedly recused themselves from decisions because they're interviewing with pharma companies. For biotechs approaching key milestones, hiring ex-FDA insiders is becoming a competitive necessity.
Read more →AbbVie and Novartis Keep Trimming U.S. Headcount as Pharma's Quiet Restructuring Rolls On
AbbVie cut 85 more jobs at its Allergan Aesthetics HQ in Irvine (287 total in 2025), while Novartis filed its third WARN notice of 2026 for East Hanover, bringing this year's cuts to 250 positions. Both companies are simultaneously building new facilities elsewhere, signaling a geographic and strategic reshuffling rather than contraction.
Read more →